STOCKHOLM – November 03, 2026 -- The U.S. Patent and Trademark Office has granted Moberg Pharma a patent on an improved dosing regimen for MOB-015, its topical onychomycosis drug, with a projected expiry in December 2041. The U.S. is the first market to grant a patent on the new dosing.